Biofrontera Inc. (BFRI) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Biofrontera Inc. (BFRI) Bundle
As an investor or analyst, this [Symbol] DCF Calculator is your go-to resource for accurate valuations. Equipped with real data from Biofrontera Inc., you can adjust forecasts and immediately observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.2 | 18.8 | 24.1 | 28.7 | 34.1 | 37.3 | 40.8 | 44.6 | 48.8 | 53.4 |
| Revenue Growth, % | 0 | -28.01 | 27.86 | 18.98 | 18.82 | 9.41 | 9.41 | 9.41 | 9.41 | 9.41 |
| EBITDA | -8.1 | -7.5 | -36.8 | .9 | -18.5 | -16.5 | -18.1 | -19.8 | -21.7 | -23.7 |
| EBITDA, % | -31.12 | -39.75 | -152.52 | 3.26 | -54.16 | -44.35 | -44.35 | -44.35 | -44.35 | -44.35 |
| Depreciation | .7 | .6 | .5 | 1.2 | 1.1 | 1.1 | 1.2 | 1.3 | 1.5 | 1.6 |
| Depreciation, % | 2.55 | 2.98 | 2.24 | 4.09 | 3.12 | 3 | 3 | 3 | 3 | 3 |
| EBIT | -8.8 | -8.1 | -37.3 | -.2 | -19.5 | -17.5 | -19.1 | -20.9 | -22.9 | -25.1 |
| EBIT, % | -33.67 | -42.73 | -154.76 | -0.83002 | -57.28 | -46.9 | -46.9 | -46.9 | -46.9 | -46.9 |
| Total Cash | 7.3 | 8.1 | 24.5 | 27.8 | 1.4 | 20.3 | 22.2 | 24.3 | 26.5 | 29.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.8 | 3.3 | 3.8 | 7.4 | 5.2 | 6.9 | 7.5 | 8.2 | 9.0 | 9.9 |
| Account Receivables, % | 18.28 | 17.45 | 15.7 | 25.83 | 15.15 | 18.48 | 18.48 | 18.48 | 18.48 | 18.48 |
| Inventories | 10.5 | 7.1 | 4.5 | 7.2 | 10.9 | 11.4 | 12.5 | 13.7 | 15.0 | 16.4 |
| Inventories, % | 40.03 | 37.62 | 18.5 | 25 | 32.02 | 30.63 | 30.63 | 30.63 | 30.63 | 30.63 |
| Accounts Payable | 7.2 | 1.5 | .7 | 1.3 | 8.9 | 5.1 | 5.6 | 6.2 | 6.7 | 7.4 |
| Accounts Payable, % | 27.55 | 8.03 | 2.73 | 4.46 | 26.14 | 13.78 | 13.78 | 13.78 | 13.78 | 13.78 |
| Capital Expenditure | -.5 | .0 | .0 | .0 | .0 | -.2 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | -2.05 | 0 | -0.04564315 | -0.13252 | -0.01467524 | -0.44955 | -0.44955 | -0.44955 | -0.44955 | -0.44955 |
| Tax Rate, % | -0.06959288 | -0.06959288 | -0.06959288 | -0.06959288 | -0.06959288 | -0.06959288 | -0.06959288 | -0.06959288 | -0.06959288 | -0.06959288 |
| EBITAT | -8.8 | -8.1 | -37.4 | -.3 | -19.5 | -17.5 | -19.1 | -20.9 | -22.9 | -25.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.8 | -8.4 | -35.5 | -4.8 | -12.3 | -22.5 | -19.3 | -21.2 | -23.1 | -25.3 |
| WACC, % | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 | 10.09 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -83.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -26 | |||||||||
| Terminal Value | -319 | |||||||||
| Present Terminal Value | -198 | |||||||||
| Enterprise Value | -281 | |||||||||
| Net Debt | 4 | |||||||||
| Equity Value | -285 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -184.53 |
What You Will Receive
- Flexible Forecast Inputs: Adjust key assumptions (growth %, profit margins, discount rates) to explore various scenarios.
- Comprehensive Data: Biofrontera Inc.’s financial information pre-loaded to facilitate your analysis.
- Automated DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Tailored and Professional: A refined Excel model that can be customized to meet your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating forecasts, confirming strategies, and enhancing efficiency.
Key Features
- Customizable Financial Inputs: Adjust essential metrics like revenue projections, profit margins, and R&D expenditures.
- Instant DCF Valuation: Quickly calculates intrinsic value, net present value (NPV), and other financial metrics.
- High-Precision Analytics: Leverages Biofrontera Inc.'s (BFRI) actual financial data for accurate valuation results.
- Effortless Scenario Testing: Easily explore various assumptions and analyze their impacts on outcomes.
- Efficiency Booster: Streamlines the valuation process, eliminating the need for complex model creation from the ground up.
How It Works
- Download: Get the pre-prepared Excel file featuring Biofrontera Inc.'s (BFRI) financial metrics.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and instantly compare the results.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose This Calculator for Biofrontera Inc. (BFRI)?
- Designed for Industry Experts: A sophisticated tool utilized by healthcare analysts, financial advisors, and investors.
- Comprehensive Data: Biofrontera Inc.’s historical and anticipated financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly test various projections and assumptions.
- Concise Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Investors: Accurately assess Biofrontera Inc.’s (BFRI) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Biofrontera Inc. (BFRI).
- Consultants: Easily customize the template for valuation reports tailored to Biofrontera Inc. (BFRI) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation techniques in the biotech sector.
What the Template Contains
- Preloaded BFRI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.